BGMA Warns No-Deal Brexit Will Harm Depleted UK Stockpile
As European Governments Brace For Possible Second Wave Of COVID-19
While the UK’s drugs stockpile is depleting due to high demand caused by the coronavirus pandemic, a no-deal Brexit in January 2021 may further harm medicines supply during a possible second wave of COVID-19.
You may also be interested in...
Despite Brexit uncertainty and travel restrictions that have just been imposed on the UK, the country’s generics industry is not expected to suffer major disruptions.
New UK licensing procedures for biosimilars are about to be set out by the MHRA that will reduce the clinical trial data burden for applicants.
While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic eﬀectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.